drugset / Trial / NCT02035020
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to investigate whether the treatment with IFN gamma can induce significant accumulation of frataxin in FRDA patients, a possibility suggested by pre-clinical evidence in an animal model of the disease.
Timeline
- Start
- 2013-05
- Primary completion
- 2014-07-30
- Completion
- 2014-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon gamma-1b | Protein / enzyme biologic | 200 ug | Subcutaneous |